AnaptysBio, Inc. $ANAB Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. trimmed its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 7.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 153,356 shares of the biotechnology company’s stock after selling 12,698 shares during the period. Charles Schwab Investment Management Inc. owned 0.52% of AnaptysBio worth $2,851,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ANAB. HighMark Wealth Management LLC acquired a new stake in shares of AnaptysBio in the 1st quarter worth approximately $1,710,000. Two Sigma Investments LP lifted its stake in AnaptysBio by 66.4% during the fourth quarter. Two Sigma Investments LP now owns 352,034 shares of the biotechnology company’s stock valued at $4,661,000 after purchasing an additional 140,457 shares during the last quarter. Moody Aldrich Partners LLC acquired a new stake in AnaptysBio during the first quarter valued at approximately $1,547,000. BIT Capital GmbH acquired a new stake in AnaptysBio during the first quarter valued at approximately $473,000. Finally, Sanofi acquired a new stake in AnaptysBio during the fourth quarter valued at approximately $10,882,000.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ANAB shares. Guggenheim reissued a “buy” rating and set a $90.00 target price (up from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. Wedbush increased their target price on shares of AnaptysBio from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday, August 7th. UBS Group restated a “neutral” rating and issued a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. HC Wainwright upgraded shares of AnaptysBio from a “neutral” rating to a “buy” rating and upped their price target for the company from $22.00 to $38.00 in a research report on Wednesday, June 4th. Finally, JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $46.13.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of the firm’s stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total value of $493,202.25. Following the completion of the sale, the director owned 4,965 shares in the company, valued at approximately $117,025.05. This trade represents a 80.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 33.50% of the stock is owned by corporate insiders.

AnaptysBio Stock Up 1.0%

Shares of ANAB opened at $20.33 on Friday. The company’s fifty day moving average is $23.31 and its 200-day moving average is $20.89. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $40.70. The firm has a market cap of $569.24 million, a price-to-earnings ratio of -4.54 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The business had revenue of $22.26 million for the quarter, compared to analyst estimates of $11.55 million. As a group, research analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.